Pfizer to explore pneumococcal jab with 3rd booster of Covid vax

  • | Monday | 24th May, 2021

Pfizer on Monday announced a study to explore coadministration of its pneumococcal vaccine along with a third dose of the Pfizer-BioNTech Covid-19 vaccine in older adults. Pfizer CEO Albert Bourla had announced that Covid vaccine recipients will “likely” need a third dose between six to 12 months after they're fully vaccinated. The company is now testing a third booster shot of its vaccine on fully vaccinated people. US pharmaceutical Moderna in its Phase 2 study found that a third booster shot of its Covid vaccine can rapidly increase the level of antibodies in previously inoculated people. The 20vPnC candidate vaccine is in development for the prevention of invasive disease and pneumonia caused by 20 serotypes of Streptococcus pneumoniae in the vaccine in adults ages 18 years and older.

Pfizer on Monday announced a study to explore coadministration of its pneumococcal vaccine along with a third dose of the Pfizer-BioNTech Covid-19 vaccine in older adults. Pfizer in a statement announced that “the first enrolled subjects have received their immunisations as part of a new study in adults ages 65 or older exploring the coadministration of the companys 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech Covid-19 vaccine currently authorised by the Food and Drug Administration (FDA) under an emergency use authorisation (EUA)”. The trial aims to describe safety when both vaccines are co-administered with follow-up six months after vaccination and to describe immune responses produced by each of the vaccines. The trial will include 600 adults who will be recruited from the pivotal Phase 3 Pfizer-BioNTech Covid-19 vaccine trial and will have received their second dose of the vaccine at least six months prior to entering the coadministration study. Pfizer CEO Albert Bourla had announced that Covid vaccine recipients will “likely” need a third dose between six to 12 months after theyre fully vaccinated. The company is now testing a third booster shot of its vaccine on fully vaccinated people. US pharmaceutical Moderna in its Phase 2 study found that a third booster shot of its Covid vaccine can rapidly increase the level of antibodies in previously inoculated people. The 20vPnC candidate vaccine is in development for the prevention of invasive disease and pneumonia caused by 20 serotypes of Streptococcus pneumoniae in the vaccine in adults ages 18 years and older.

If You Like This Story, Support NYOOOZ

NYOOOZ SUPPORTER

NYOOOZ FRIEND

Your support to NYOOOZ will help us to continue create and publish news for and from smaller cities, which also need equal voice as much as citizens living in bigger cities have through mainstream media organizations.


Stay updated with all the Latest Kashmir headlines here. For more exclusive & live news updates from all around India, stay connected with NYOOOZ.

Related Articles